Your browser doesn't support javascript.
Discussion on artemisinin and its derivatives for treatment of COVID-19
Drug Evaluation Research ; 43(4):606-612, 2020.
Artículo en Chino | CAB Abstracts | ID: covidwho-1352919
ABSTRACT
Since the initial cases of the Coronavirus Disease in 2019 (COVID-19) occurred in Wuhan in December 2019, more and more cases have been found and confirmed, not only in central China but also in other countries. Given there are still no effective drugs many approved "old drugs" are in clinical test for treating COVID-19 at present. Artemisinin, a first-line antimalarial drug recommended by WHO, has been validated to possess a variety of pharmacological effects, including, without limitation, antiinflammatory, immune regulation, anti-pulmonary fibrosis, antibacterial, antiviral and cardiovascular effects, and the like. In this paper, various pharmacological effects of Artemisinin and its derivatives have been summarized, with the emphasis on the mechanism of action, so as to explore its potential medicinal value, especially for treating COVID-19.

Texto completo: Disponible Colección: Bases de datos de organismos internacionales Base de datos: CAB Abstracts Idioma: Chino Revista: Drug Evaluation Research Año: 2020 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos de organismos internacionales Base de datos: CAB Abstracts Idioma: Chino Revista: Drug Evaluation Research Año: 2020 Tipo del documento: Artículo